| Literature DB >> 35805373 |
Monika Hejna1, Dominika Kapuścińska1, Anna Aksmann1.
Abstract
The pollution of the aquatic environment has become a worldwide problem. The widespread use of pesticides, heavy metals and pharmaceuticals through anthropogenic activities has increased the emission of such contaminants into wastewater. Pharmaceuticals constitute a significant class of aquatic contaminants and can seriously threaten the health of non-target organisms. No strict legal regulations on the consumption and release of pharmaceuticals into water bodies have been implemented on a global scale. Different conventional wastewater treatments are not well-designed to remove emerging contaminants from wastewater with high efficiency. Therefore, particular attention has been paid to the phycoremediation technique, which seems to be a promising choice as a low-cost and environment-friendly wastewater treatment. This technique uses macro- or micro-algae for the removal or biotransformation of pollutants and is constantly being developed to cope with the issue of wastewater contamination. The aims of this review are: (i) to examine the occurrence of pharmaceuticals in water, and their toxicity on non-target organisms and to describe the inefficient conventional wastewater treatments; (ii) present cost-efficient algal-based techniques of contamination removal; (iii) to characterize types of algae cultivation systems; and (iv) to describe the challenges and advantages of phycoremediation.Entities:
Keywords: contaminants of emerging concern; ecotoxicology; non-steroidal anti-inflammatory drugs; pharmaceuticals; phycoremediation; wastewater treatment
Mesh:
Substances:
Year: 2022 PMID: 35805373 PMCID: PMC9266021 DOI: 10.3390/ijerph19137717
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Occurrence of selected NSAIDs in surface water, wastewater and drinking/underground water in different locations.
| Surface Water (ng/L) | Reference | Wastewater (Effluents (E)/Influents (I)) (ng/L) | Reference | Drinking Water (DW)/Underground Water (UW) (ng/L) | Reference | Area |
|---|---|---|---|---|---|---|
|
| ||||||
| <0.3–56.0 | [ | | | | UK | |
|
| ||||||
| <0.5–261.0 | [ | | | | | UK |
|
| ||||||
| <0.3–55.0 | [ | | | | | UK |
|
| ||||||
| <0.5–4.0 | [ | | | | | UK |
Toxic effects of selected NSAIDs on various non-target aquatic organisms, based on [2,35,72].
| Compound | Tested Organisms | Tested | Exposure Time | Effect (Acute and Chronic) | Reference | |
|---|---|---|---|---|---|---|
|
| ||||||
| Ibuprofen |
| Chlorophyta | 315.0 (mg/L) | Growth inhibition (EC50). | [ | |
|
| Tracheophyta | 22.0 (mg/L) | 7 d | Growth inhibition (EC50). | [ | |
|
| ||||||
| Ibuprofen |
| Pisces | 7.1 (mg/L) | 12, 24, 48, 72, 96 h | Genotoxic effects: DNA damage (the intensity of the tail DNA relative to the head). | [ |
|
| 1.5, 3.0, 4.5, 6.0, 7.5, 9.0, 11.5 (mg/L) | 96 h | Teratogenic effect: higher mortality of oocytes and delay in hatching. Delay in embryo development and embryo malformations. | [ | ||
|
| 0.04, 0.2, 1.0, 5.0, 25.0 (mg/L) | 56 h | Reproduction disruption: disruption of cardiac physiology of embryos. | [ | ||
|
| 0.000092 (mg/L) | Genotoxic effects: DNA fragmentation, apoptosis and genomic alterations. | [ | |||
|
| 10.0, 100.0, 1000.0 (mg/L) | 14 d | Genotoxic effects: disruption of gonadotropin production. Increase in the transcription level of genes involved in the acceleration of gametogenesis, maturation of oocytes in females and spermatogenesis in males. | [ | ||
|
| 0.0001 (mg/L) | 21 d | Genotoxic effects: influence of sex steroid hormones. Changes in the production of estradiol (E2). Endocrine-disrupting effect: significant increase in vitellogenin (VTG). | [ | ||
|
| 0.01, 0.1, 1.0, 10.0, 100.0, 1000.0 (mg/L) | 132 d | Genotoxic effects: disruption of reproduction processes and early life stages. Reproduction disruption: delay in spawning. | [ | ||
|
| Molluscs | 1.0, 100.0 (mg/L) | 7 d | Gene expression disorder: differences in gene transcription in gill tissue. Significant upregulation of CYTP450 genes. | [ | |
|
| 0.2, 1.0, 3.0 (mM) | 1 h | Acute cytogenotoxic effect: irreversible DNA damage and decrease in LMS. | [ | ||
|
| 1.0, 9.0, 35.0 (nM) | 96 h | Oxidative stress: increase in activity levels of SOD, CAT, GPx and GST. | [ | ||
|
| 0.1, 5.0, 10.0, 50.0 (mg/L) | 35 d | Acute cytogenotoxic effect: decrease in LMS in haemolymph. | [ | ||
|
| 0.1, 5.0, 10.0, 50.0 (mg/L) | 14 d | Oxidative stress: increase in GPx activity and LPO. | [ | ||
|
| Crustaceans | 0.05, 0.5, 5.0, 50.0, 500.0 (ng/g) | 10 d | Oxidative stress: significant increase in DBF, GST and GPX activity. | [ | |
|
| 2.9 (mg/L) | 48, 96 h | Genotoxicity effect: DNA damage. | [ | ||
|
| 20.0, 40.0, 80.0 (mg/L) | 24 h | Endocrine disruption: deregulation of eicosanoid metabolism, the endocrine system and oogenesis. | [ | ||
|
| 20.0, 40.0, 80.0 (mg/L) | Decrease in reproduction or complete reproduction inhibition. | [ | |||
|
| 0.0005, 0.005, 0.05 (mg/L) | 21 d, 6 h | Oxidative stress: the induction of antioxidant enzymes (GST, SOD and CAT). Reproduction disruption: significant decrease in the total number of broods per female, body length and intrinsic growth rate. | [ | ||
|
| Polychaeta | 5.0, 500.0 (ng/g) | Genotoxic effect: DNA damage. | [ | ||
|
| ||||||
| Diclofenac |
| Chlorophyta | 72.0 (mg/L) | Growth inhibition (EC50). | [ | |
|
| 185.7 (mg/L) | 96 h | Growth inhibition (EC50). | [ | ||
|
| 20.0 (mg/L) | 96 h | Growth retardation. | [ | ||
|
| 23.0 (mg/L) | Inhibition of reproduction. | [ | |||
|
| Tracheophyta | 7.5 (mg/L) | 7 d | Growth inhibition (EC50). | [ | |
|
| 0.0003 (mg/L) | 48 h | Hormetic effects in mitochondrial activity in spores. | [ | ||
|
| ||||||
| Diclofenac |
| Pisces | 0.001 (mg/L) | 96 h | Oxidative stress: induction of enzymatic activity. | [ |
|
| 0.001 (mg/L) | 96 h | Alterations in hematological and biochemical activities. | [ | ||
|
| 17.6 (mg/L) | 12, 24, 48, 72, 96 h | Genotoxic effects: DNA damage (the intensity of the tail DNA relative to the head). | [ | ||
|
| 1.25, 2.5 and 5.0 (mg/L) | 21 d | Deformations: histopathological changes in gills, liver and kidney. Lesions included necrosis of epithelial cells. | [ | ||
| 12.5 (mg/L) | 48 h | Oxidative stress: deregulation of kinase activities. Metabolic disorders: deregulation of gluconeogenesis and lipid metabolism. | [ | |||
|
| 0.2, 2.0, 20.0 (mg/kg) | Metabolic disorders: interferences with metabolic pathways. Oxidative stress: increase in the activity of SOD, GPx and GSH. | [ | |||
|
| 0.005 (mg/L) | 28 d | Deformations: renal lesions and alterations in the gills. | [ | ||
|
| 7.1, 37.0,78.0 (mg/L) | 14 d | Morphological abnormalities. | [ | ||
|
| 25.0 (mg/L) | Behavioral changes: respiratory disorders and loss of balance. | [ | |||
|
| 0.2, 2.0, 20.0 (mg/L) | 21 d | Oxidative stress: significant reduction in SOD activity, increase in activity of GSH and GST. Disruption of antioxidant defense systems in the liver. | [ | ||
|
| Rotatoria | 25.0 (mg/L) | 48 h | Reproduction retardation. | [ | |
|
| Molluscs | 0.2, 0.5, 0.8 (mM) | 1 h | Acute cytogenotoxic effect: significant DNA damage. | [ | |
|
| 1000.0 (mg/L) | 96 h | Oxidative stress: increase in GST activity, LPO expression and methallothioneins (MTs) alterations. | [ | ||
|
| 0.001 (mg/L) | 96 h | Oxidative stress: high lipid peroxidation levels. Significant reduction in haemocyte viability. | [ | ||
|
| 20.0, 200.0, 2000.0 (ng/L) | 48, 96 h | Genotoxic effects: DNA damage. Significant decrease in LMS. Gene expression upregulation. COX inhibition in gill tissue. | [ | ||
|
| Crustaceans | 13.3, 70.6 (mg/L) | 96 h | Metabolism disorder: decrease in respiration under reduced oxygen content. | [ | |
|
| 0.00001, 0.0001 (mg/L) | Osmoregulation disturbances. Effect on haemolymph osmolality and osmolality capacity. | [ | |||
|
| 2.0 (mg/L) | 7 d | Reproduction inhibition. | [ | ||
|
| 32.0 (mg/L) | 21 d | Oxidative stress. | [ | ||
|
| 9.7 (mg/L) | 48, 96 h | Genotoxicity effect: DNA damage. | [ | ||
|
| Polychaetes | From 0.6 to 842.0 (ng/L) | Reproduction disruption: decrease in swimming speed of sperm. | [ | ||
|
| 0.5, 1.0, 2.0 (mg/L) | 28 d | Gene expression upregulation: significant effect on the activity of GST enzymes. | [ | ||
|
| ||||||
| Naproxen | Ochrophyta | 102.8 (mg/L) | 72 h | Growth inhibition (EC50). | [ | |
|
| Chlorophyta | >320.0 (mg/L) | Growth inhibition (EC50). | [ | ||
|
| 0.0318 (mg/L) | 72 h | Growth inhibition (EC50). | [ | ||
|
| 101.5 (mg/L) | 72 h | Growth inhibition (EC50). | [ | ||
|
| 625.5 (mg/L) | 48 h | Growth inhibition (EC50). | [ | ||
|
| Tracheophyta | 24.2 (mg/L) | 7 d | Growth inhibition (EC50). | [ | |
|
| ||||||
| Naproxen |
| Pisces | 1.0, 100.0 (mg/L) | 14 d | Gene expression: upregulation of gene expression. Metabolism disorders: upregulation of the activity of GST by affecting glutathione S-transferase P2 (GST P2) mRNA in the intestine. | [ |
|
| 0.005, 0.05, 0.5, 5.0, 50.0 (mg/L) | Endocrine disruption: significant increase in the expression of VTG and E2 receptors genes. Reduction in conditions: decrease in the survival of juvenile animals. | [ | |||
|
| Crustaceans | 46.7 (mg/L) | 48 h | Immobilization (EC50). | [ | |
|
| 2.9 (mg/L) | 48, 96 h | Genotoxicity effect: DNA damage. Oxidative stress: increase in enzyme activity (SOD, CAT and GPx). | [ | ||
|
| 76.6, 339.2 (mg/kg) | 48 h | Genotoxicity effect: DNA damage. Oxidative stress: increase in SOD and CAT activity and decrease in GPX activity. | [ | ||
|
| 74.1 (mg/L) | 48 h | Immobilization (EC50). | [ | ||
|
| Molluscus | 0.6 to 23.0 (mg/L) | 24 h | Immunotoxic effects. Phagocytic activity, intracellular esterase activity, cell adherence and lipid peroxidation. | [ | |
|
| Cnidaria | LC50 | 24, 48, 72 h | Morphological changes: stimulation of the contraction of the body column and tentacles. Genotoxicity effect: DNA damage or instability. | [ | |
|
| ||||||
| Ketoprofen |
| Tracheophyta | 0.2, 1.2, 6.0, 30.0 (mg/L) | 4 d | Oxidative stress: alterations in enzyme activities (CAT, GSTs and CA). | [ |
|
| ||||||
| Ketoprofen |
| Crustaceans | From 1.0 to 1000.0 (mg/L) | Chronic toxicity. Effects on reproduction at the highest concentration. | [ | |
|
| 0.2, 1.2, 6.0, 30.0 (mg/L) | 4 d | Oxidative stress: alterations in enzyme activities (CAT, GSTs and CA). | [ | ||
|
| Molluscus | 0.0025 (mg/L) | 14, 30, 60 d | Alterations in immunological parameters, genotoxic effects and modulation of lipid metabolism. Reduction in lysosomal membrane stability. | [ | |
|
| 100.0 (mg/g) | 48 h | Antipyretic effect. Inhibition of symptoms of behavioral fever and influenced thermal preference. | [ | ||
Figure 1Main steps of conventional wastewater treatment, based on [134].
Examples of contaminants removed/potentially removed by selected algae species.
|
Type of | Substance | Algae Species | Removal Rate | Time | References |
|---|---|---|---|---|---|
| Antibiotic | Enrofloxacin (ENR) |
| 75–85% *,1
| | [ |
| Ciprofloxacin hydrochloride (CIP) |
| 65–85% *,1 | | [ | |
| 7-amino cephalosporanic acid (7-ACA) | >70% | 24 h | [ | ||
| Cefradine (CFD) |
| 5–14% | 8 h | [ | |
| Amoxicillin |
| 91% | 6 h | [ | |
| Clarithromycine |
| 90% | 7 d | [ | |
| NSAID | Ibuprofen | 29–31% | 42 d | [ | |
| Diclofenac | 40–60% | 31 d | [ | ||
| Naproxen |
| 59%, 73%, 2% (1, 10 and 100 mg L−1 | 30 d | [ | |
| Paracetamol | 100% * | 31 d | [ | ||
| β-blocker | Atenolol |
| 99% | 7 d | [ |
| Bisoprolol |
| 97% | 7 d | [ | |
| Metoprolol |
| 99% | 7 d | [ | |
| Other drug | Alfuzosin |
| 64% | 7 d | [ |
| Carbamazepine |
| 30% | 7 d | [ | |
| Trimethoprim |
| 60% | 7 d | [ | |
| Salicylic acid |
| >73% | 8-9 d | [ |
* approximately; 1 depending on the initial concentration of the pharmaceutical; 2 depending on the concentration of sodium acetate.
Figure 2Mechanisms of phycoremdiation.
Figure 3Factors affecting phycoremediation efficiency.
The major characteristics of algae cultivation systems, based on [261].
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Open systems | ||||||
| Open ponds | Paddle wheel | None | Limited, through surface aeration | Less control over culturing conditions; temperature fluctuations; poor light utilization by the cells; inefficient stirring; diffusion of carbon dioxide to the atmosphere; lower biomass productivity; risk of contamination; large land space requirement | Simple design; cost-efficient; low investment costs; not difficult to maintain | [ |
| Closed systems | ||||||
| Vertical column photobioreactors(bubble column photobioreactors and airlift columns) | Airlift or bubble | - | Open gas | Expensive construction materials; limited scale-up opportunities due to design constraints and inhomogeneous distribution of light inside the culture; productivity negatively affected by light-deprived zones; limited surface area for illumination; shading effect issues; photosynthetic efficiency depends on gas flow rate | Efficient mixing; high volumetric mass transfer rates; relatively homogenous culture environment; low photoinhibition; controllable growth conditions; lack of moving parts; no internal structures | [ |
| Stirred-tank photobioreactors | Mechanical agitator | Heat exchanger | Injection through sparger | Not cost-efficient; mechanical agitation requires extra energy; low surface-to-volume ratio; low harvesting efficiency; heating issues due to agitation | Appropriate light dispersion; appropriate heat and mass transfer; simple design; moderate biomass; low contamination issues; productive | [ |
| Flat-panel photobioreactors | Airlift or bubble from bottoms or | Heat exchangecoils | Open gas exchange at head space | Requires many components; short light penetration depth; frequent fouling and clean up issues; not scalable; poor temperature regulation | Cost-efficient; low space requirement; high surface-to-volume ratio; high photosynthetic efficiency; low oxygen build-up | [ |
| Horizontal tubular photobioreactors | Recirculation | Water spraying; shading; overlapping | Injection into feed | Large space requirement; high energy consumption; susceptible to photo inhibition; dissolved oxygen buildup; fouling due to algal growth; poor temperature regulation | Cost-efficient; harnessing sun | [ |
| Helical-type photobioreactors | Centrifugal pump (injection from bottom) | Heat exchanger | - | Limited commercial use associated with shear stress; fouling on the inside of the reactor | High photosynthetic efficiency through the light dilution effect and light absorbing capacity; high CO2 transfer; balance between energy input and photosynthetic efficiency; low energy requirement; low mechanical stress to cells | [ |
Figure 4Algal-based remediation systems based on [253,265,266,267,268].
Algal cells with different immobilized carriers in wastewater treatment, based on [3,265].
|
|
|
|
|
|
| Alginate | Organic carrier |
| Ni, Zn, Cd | [ |
|
| Cr (VI) | [ | ||
|
| Cu, Ni | [ | ||
| Alginate beads |
| Hg | [ | |
|
| Cu, Cd | [ | ||
| Alginate gel |
| Cr (III) | [ | |
| Alginate |
| P | [ | |
| Alginate |
| Pb | [ | |
| Alginate |
| N, P | [ | |
| Chitosan | Organic carrier | Nitrate, phosphate | [ | |
| Carrageenan beads | Organic carrier |
| Zn, Cd, Cr | [ |
| Carrageenan |
| N, P | [ | |
| Polyurethane foam | Organic carrier |
| Zn, Cd, Cr | [ |
| Carboxymethyl cellulose (CMC) beads | Organic carrier |
| U (VI) | [ |
| Silica gel | Organic carrier |
| Hg | [ |
| Glass beads | Inorganic carrier |
| Ni, Cr | [ |
Removal efficiencies of contaminants with selected algal–bacterial consortia.
| Consortium | Class of | Compound | Cultivation | Removal Rate | Contaminated | References |
|---|---|---|---|---|---|---|
| Pharmaceuticals | ||||||
| Antibiotics | Tetracycline | High-rate algal ponds | 69% | Urban wastewater | [ | |
| A/A | Paracetamol | Stirred-tank packed-bed reactor | 100% | Urban wastewater | [ | |
| NSAID | Ketoprofen | 5 mM | Wastewater | [ | ||
| NSAID | Ibuprofen | Photobioreactor operating at a hydraulic retention time | 94% | Urban wastewater | [ | |
| Nutrients | ||||||
| - | TDN | Reactor (conical flask) | 89% | Synthetic wastewater | [ | |
| - | NH4+ | 100% | Synthetic wastewater | [ | ||
| - | P | Tabular | 98% | Municipal wastewater | [ | |
| - | COD | 92% | Municipal wastewater | [ | ||
| COD | Waste | 78% | Domestic wastewater | [ | ||
| - | N | 100% | Synthetically made | [ | ||
| Metals | ||||||
| - | Cu | Laboratory-scale photo-rotating biological contactor | 50% | Drainage wastewater | [ | |
| - | Cu | - | 62% | Industrial wastewater | [ | |
| - | Cu | - | 8.5 mg/g | Synthetic wastewater | [ | |
A/A: analgesics and antipyretics; BOD: biochemical oxygen demand; TP: total phosphorus; TN: total nitrogen; DOC: dissolved organic carbon; COD: chemical oxygen demands.